story of the week
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-Line Treatment for ER+, HER2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002)
Clin. Cancer Res 2021 Nov 22;[EPub Ahead of Print], X Hua, XW Bi, JL Zhao, YX Shi, Y Lin, ZY Wu, YQ Zhang, LH Zhang, AQ Zhang, H Huang, XM Liu, F Xu, Y Guo, W Xia, RX Hong, KK Jiang, C Xue, X An, YY Zhong, S Wang, JJ Huang, ZY YuanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.